Crossmark

Optimising Prescription of Treatment In older patients with Mild hypertension at Increased risk of Serious adverse Events (OPTIMISE2): protocol for a primary care based, open-label, randomised controlled non-inferiority trial

Crossref DOI link: https://doi.org/10.1186/s13063-026-09508-7

Published Online: 2026-02-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Carr, Melanie

Kenealy, Nicola

Yu, Ly-Mee

Moschandreas, Joanna

Hobbs, F. D. Richard

de Lusignan, Simon

Ford, Gary

Petrou, Stavros

Shanyinde, Milensu

McCartney, David

Clegg, Andrew

Mant, Jonathan

Payne, Rupert

Williams, Marney

Ogden, Margaret

McManus, Richard J.

Sheppard, James P. https://orcid.org/0000-0002-4461-8756
Funding

Funding for this research was provided by:

Health Technology Assessment Programme (NIHR133774)
License Information

Text and Data Mining valid from 2026-02-14

Version of Record valid from 2026-03-23
More Information

Article History

Received: 7 July 2025

Accepted: 28 January 2026

First Online: 14 February 2026

Declarations

:

: This trial was approved by an NHS Research Ethics Committee (East Midlands - Leicester Central Research Ethics Committee. REC Ref: 23/EM/0054) and the Medicines and Healthcare Products Regulatory Authority (MHRA; ref CTA 21584/0465/001-0002) via combined review. Full approvals were received on 18th September 2023.

: None.

Document is current

Any future updates will be listed below